Gene
PIK3R1
PIK3R1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (21), Actionable biomarkers (2), Trial mentions (25), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PIK3R1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 25 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 4 of 8,275 | 0.05% | 74 of 11,460 | 0.65% |
| 2022 | 3 of 8,285 | 0.04% | 100 of 13,598 | 0.74% |
| 2021 | 1 of 8,692 | 0.01% | 137 of 15,045 | 0.91% |
| 2020 | 0 of 7,640 | 0.00% | 126 of 14,459 | 0.87% |
| 2019 | 2 of 7,300 | 0.03% | 107 of 12,159 | 0.88% |
| 2018 | 0 of 6,927 | 0.00% | 116 of 11,854 | 0.98% |
| 2017 | 0 of 6,558 | 0.00% | 114 of 11,595 | 0.98% |
Showing 10 of 37 years.
Assay-provider ledger (21)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | March 01, 2025 |
| DAKO | Unclassified | Clinical validation | 1 | March 01, 2025 |
| Promega | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Thermo Fisher | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 1 | September 09, 2020 |
Showing 5 of 21 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PIK3R1 oncogenic mutation | Pi3k Pathway Inhibitors | response-associated | endometrial carcinoma | Cancer Genome Interpreter |
| PIK3R1 oncogenic mutation | Akt Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
Trial mentions (25)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06694363 | Trial eligibility (AACT) |
| NCT05843253 | Trial eligibility (AACT) |
| NCT07175415 | Trial eligibility (AACT) |
| NCT02644122 | Trial eligibility (AACT) |
| NCT04439188 | Trial eligibility (AACT) |
Showing 5 of 25 trial mentions.
Target-disease associations (786)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| 3-hydroxy-3-methylglutaryl-CoA synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| AKT2-related familial partial lipodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 786 associations.
Vendor sourcing (141)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal pro... | View ClinVar record SCV002521331.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The PIK3R1 c.104G>C; p.Gly35Ala variant (rs1017086766), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID:... | View ClinVar record SCV007331718.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Children ≥ 2 years and ≤ 18 years of age at the time of first diagnosis and less than 21 years at the time of inclusion 2. Performance status: Karnofsk... | View trial NCT07175415 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | PIK3R1 | View trial NCT07175415 |
| Aixial Group | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patient is male or female and between the age of 1 to 6 years old at time of the first study procedure. 2. Patient weighs ≥8 and ≤37 kg at baseline. 3.... | View trial NCT05693129 |
Showing 5 of 141 sourcing records.
Trial-cited literature (1,656)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Traditional Chinese Medicine Syndrome Differentiation of Adult Patients With Type 2 Diabetes and Metabolic Syndrome: Protocol for a Cross-Sectional Study. | JMIR research protocols | 2026 | 1 |
| Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. | The New England journal of medicine | 2025 | 52 |
| Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics | 2025 | 27 |
| Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer. | ESMO open | 2025 | 4 |
| PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. | JCO precision oncology | 2025 | 2 |
Showing 5 of 1,656 papers.
Protein variant mentions (30)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A10V | 1 | 2015 | PMID 25741868 |
| p.A304V | 1 | 2015 | PMID 25741868 |
| p.D620E | 1 | 2015 | PMID 26552420 |
| p.D910A | 1 | 2009 | PMID 19644473 |
| p.D933A | 1 | 2009 | PMID 19644473 |
Showing 5 of 30 variants.
Human sample screening reference (8)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.R348* | CPTAC-2 | Not Reported; Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Ductal and Lobular Neoplasms; Squamous Cell Neoplasms; Other and unspecified female genital organs; Colon; Breast; Retroperitoneum and peritoneum; Rectum; Ovary | 1 | 328 | 0.30% | 0.05% to 1.71% |
| p.R348* | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 4 | 1,815 | 0.22% | 0.09% to 0.57% |
| p.R348* | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 1 | 1,098 | 0.09% | 0.02% to 0.51% |
| p.R348* | TCGA-COAD | Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Complex Epithelial Neoplasms; Rectosigmoid junction; Colon | 1 | 461 | 0.22% | 0.04% to 1.22% |
| p.R348* | TCGA-READ | Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Colon; Unknown; Rectum; Rectosigmoid junction; Connective, subcutaneous and other soft tissues | 3 | 171 | 1.75% | 0.60% to 5.03% |
Showing 5 of 8 cohort observations.
Literature-extracted relations (197)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Trabectedin | Chemical | associate |
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination. | 2022 |
| Decitabine | Chemical | negative_correlate |
Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction <i>via</i> Modulating PD-1 Methylation in Immune Thrombocytopenia. | 2021 |
| Sirolimus | Chemical | negative_correlate |
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. | 2018 |
| Flavonoids | Chemical | associate |
Protective effects of flavonoids against Alzheimer's disease-related neural dysfunctions. | 2017 |
| Aspirin | Chemical | associate |
Role of Aspirin in Breast Cancer Survival. | 2017 |
Showing 5 of 197 relation assertions.
Organizations publishing (895)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 66 | 1999 to 2023 |
| The University of Texas System | Academic | 64 | 2004 to 2025 |
| Government of the United States of America | Government | 63 | 2004 to 2025 |
| Harvard Medical School | Academic | 48 | 2004 to 2024 |
| Dana-Farber Cancer Institute | Other | 47 | 2009 to 2025 |
Showing 5 of 895 organizations.
Where PIK3R1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
695 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.